Download Free Medical Dry Eye PowerPoint Presentation

Dry Eye PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Dry Eye” by Dr.Ajai Agrawal.

This medical PowerPoint presentation is about dry eye, a common eye condition that occurs when your eyes dont produce enough tears, or when your tears evaporate too quickly. It can cause a variety of symptoms such as dryness, irritation, redness, blurred vision, and sensitivity to light.

There are two main types of dry eye: aqueous deficiency and evaporative. Aqueous deficiency occurs when there is a lack of water in the tear film, while evaporative dry eye occurs when there is an issue with the quality of the oil layer of the tear film.

There are several factors that can contribute to dry eye, including age, gender, certain medications, medical conditions, environmental factors, and lifestyle habits. Treatment options may include artificial tears, prescription eye drops, lifestyle changes, and in some cases, surgery.

Its important to consult with an eye doctor if you experience persistent dry eye symptoms, as they can help identify the underlying cause and recommend appropriate treatment.

Tags : dry eye, aqueous deficiency, evaporative dry eye, Ophthalmology, Ophthalmology PowerPoint presentation

Published on : Jun 20, 2023 | Views : 638 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Dry Eye Dr.Ajai Agrawal Additional Professor Department of Ophthalmology AIIMS, Rishikesh 1
Slide 2-

Acknowledgement Photographs in the presentation are courtesy of Dr.Brad Bowling (Kanski’s Clinical Ophthalmology) 2
Slide 3-

Learning Objectives At the end of this class the students shall be able to : Define dry eye disease. • Understand predisposing and aetiological factors responsible for dry eye disease • Comprehend clinical features and tests for the above condition • Understand fundamentals of managing dry eye depending on the severity of disease 3
Slide 4-

What is Dry Eye Disease? Dry eye disease (DED) is a condition caused by many factors that result in inflammation of the eye and tear-producing glands. Inflammation can decrease the ability of the eye to produce normal tears that protect the surface of the eye and keep it moist and lubricated. 4
Slide 5-

Definition Dry eye is not a trivial complaint. It can cause significant discomfort and affect quality of life significantly. In 1995 the National Eye Institute defined dry eye disease (DED) as “ a disorder of the tear film due to tear deficiency or excessive tear evaporation which causes damage to the interpalpebral ocular surface and is associated with symptoms of ocular discomfort”. 5
Slide 6-

Definition In 2007 the International Dry Eye Workshop defined it as “ a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.” 6
Slide 7-

Dry Eye is more than a red eye. 7
Slide 8-

Dry Eye Affects Quality of Life 8
Slide 9-

Lacrimal Glands Secretomotor Nerve Impulses Tears Support and Maintain Ocular Surface Ocular Surface Neural Stimulation The Healthy Eye Normal tearing depends on a neuronal feedback loop 9
Slide 10-

Lacrimal Glands: Neurogenic Inflammation T-cell Activation Cytokine Secretion into Tears Interrupted Secretomotor Nerve Impulses Tears Inflame Ocular Surface Cytokines Disrupt Neural Arc Inflammation disrupts normal neuronal control of tearing Dry Eye Disease: An Immune-Mediated Inflammatory Disorder 10
Slide 11-

Multiple Factors in Dry Eye Transient discomfort May be stimulated by environmental conditions Inflammation and ocular surface damage Altered tear film composition 1de Paiva and Pflugfelder. In: Dry Eye and Ocular Surface Disorders. 2004;2Pflugfelder et al. In: Dry Eye and Ocular Surface Disorders. 2004. 11
Slide 12-

Role of Inflammation in Chronic Dry Eye Inflammation may be present but not clinically apparent Cycle of inflammation and dysfunction If untreated, inflammation can damage lacrimal gland and ocular surface Consequences: Lower tear production Altered corneal barrier function Pflugfelder. Am J Ophthalmol. 2004. 12
Slide 13-

Healthy Tears A complex mixture of proteins, mucin, and electrolytes Antimicrobial proteins:Lysozyme, lactoferrin Growth factors & suppressors of inflammation: EGF, IL-1RA Soluble mucin secreted by goblet cells for viscosity Electrolytes for proper osmolarity Image adapted from: Dry Eye and Ocular Surface Disorders. 2004. Stern et al. In: Dry Eye and Ocular Surface Disorders. 2004. 13
Slide 14-

Tears in Chronic Dry Eye Decrease in many proteins Decreased growth factor concentrations Altered cytokine balance promotes inflammation Soluble mucin 5AC greatly decreased Due to goblet cell loss Impacts viscosity oftear film Proteases activated Increased electrolytes Solomon et al. Invest Ophthalmol Vis Sci. 2001. Zhao et al. Cornea. 2001. Ogasawara et al. Graefes Arch Clin Exp Ophthalmol. 1996. Image adapted from: Dry Eye and Ocular Surface Disorders. 2004. 14
Slide 15-

Who Is Likely to Have Dry Eye?How Do We Diagnose It? 15
Slide 16-

Dry Eye: Multifactorial nature Elderly woman Contact lens user Post menopausal Taking glaucoma medications Working for long hours in front of computer Air-conditioned environment 16
Slide 17-

Patient Types with High Incidence of Dry Eye Disease Women aged 50 or older Women using postmenopausal hormone replacement therapy Those with ocular co-morbidities – xerophthalmia, cicatrical pemphigoid, atopic keratoconjunctivitis, ocular rosacea Contact lens wearers Smokers 17
Slide 18-

Dry Eye Disease: Predisposing Factors Ageing Menopause - Decreased Androgens Allergy Response Environmental Stresses Contact Lens Wear Wind Air Pollution Ocular Surgery (LASIK, Corneal Transplant) Medications Low Humidity: Heating/AC Lack of Sleep Use of Computer Terminals 18
Slide 19-

Medications That May Contributeto Dry Eye Disease Systemic Anti-hypertensives Anti-androgens Anti-cholinergics Antidepressants Cardiac Anti-arrhythmic Drugs Parkinson’s Disease Agents Antihistamines Topical Preservatives in Tears 19
Slide 20-

Dry Eye Disease:Autoimmune Triggers Systemic Autoimmunity Rheumatoid Arthritis Lupus Sjögren’s Syndrome Graft vs. Host Disease All can result in immune-mediated inflammation in the eye. Inflammatory mediators secreted into tears. Promote inflammation of ocular surface. 20
Slide 21-

Symptoms of Ocular Surface Disease Current Triggers of Dry Eye Disease 21
Slide 22-

22
Slide 23-

23
Slide 24-

Dry Eye Disease Symptoms Discomfort Dryness Burning, Stinging Foreign-Body Sensation Gritty Feeling, Stickiness Blurry Vision Photophobia, Itching, Redness Note: Symptoms seldom correlate with clinical signs 24
Slide 25-

Slitlamp Fluorescein Dye Stain Mild Severe Clinical Presentation Can Vary in Severity 25
Slide 26-

Slit lamp examination Increased debris/mucin strands in tear film Inspection of tear meniscus at lid margin. Normal thickness – 1mm, convex. < 0.5mm – tear deficiency. In severe cases – Marginal tear meniscus is concave, small & absent. 26
Slide 27-

Filaments ( comma shaped) over corneal surface which move on blinking 27
Slide 28-

Mucous plaques – semi-transparent, white to grey, slightly elevated lesionsStain with rose bengal. 28
Slide 29-

Bulbar conjunctival vessels may be dilated  Red Eye Corneal surface – irregularity/ dry areas. Blinking – incomplete/infrequent. Meibomian gland dysfunction/ blepharitis. 29
Slide 30-

Diagnostic Tests Appropriate choice of test helps the clinician to arrive at an accurate diagnosis as well as for individualization of therapy. 30
Slide 31-

31
Slide 32-

1. Basic Secretion Test Purpose – to measure basal secretion by eliminating reflex tearing. < 5mm  hyposecretion. 32
Slide 33-

2. Schirmer’s Test I Purpose – measurement of the total (reflex + basal) tear secretion. Eyes should not be manipulated before starting this test. 33
Slide 34-

Schirmer Test 34
Slide 35-

Normal wetting 10-15 mm Dry Eye Mild 9-14 mm Moderate 4-8 mm Severe < 4 mm 35
Slide 36-

Schirmer Test II Purpose – to ascertain reflex secretion. Measured after 2 minutes. After Strips are placed in eye un-anaeasthetized nasal mucosa is irritated. Less than 15 mm failure of reflex secretion. 36
Slide 37-

Rose Bengal staining Purpose - to ascertain indirectly, the presence of reduced tear volume by the detection of damaged epithelial cells. Useful in early stages of conjunctivitis sicca and keratoconjunctivitis sicca syndrome. 37
Slide 38-

Rose Bengal Staining Positive test – show triangular stipple staining of nasal and temporal bulbar conjunctiva in the interpalpebral area & possible punctate staining of the cornea (esp. lower 2/3rd). 38
Slide 39-

Rose Bengal Staining False positive – Chronic conjunctivitis Acute chemical conjunctivitis, secondary to hair spray use and drugs such as tetracaine & cocaine Exposure keratitis Superficial punctate keratitis, secondary to toxic or idiopathic phenomena. Foreign bodies in conjunctiva. 39
Slide 40-

Modified van Bijsterveld conjunctival rose bengal grading map. The density of rose bengal staining is recorded on a scale of 0-3 for each of 6 areas of the conjunctiva, and then summed for each eye. 40
Slide 41-

Fluoroscein Dye Test 41
Slide 42-

Tear film Break-up time (BUT) Time of appearance of first dry spot from the last blink. Tests for stability of tear film. 42
Slide 43-

43
Slide 44-

Tear film Break-up time (BUT) Wetting time > 20 s  Normal Tear film stability. BUT Averages b/w 25-30 s in Normal individuals. Women < Men Less in elderly BUT < 10 s  significant tear film instability. 44
Slide 45-

NEI Workshop grading Efron Scale Grade 0 = no staining Grade 1 = trace staining Grade 2 = mild staining Grade 3 = moderate staining Grade 4 = severe staining 45
Slide 46-

Other tests Practical Double Vital Staining for Ocular Examination Corneal Residence Time Test or Tear Clearance Rate (TCR) Tear Function Index Tear Film Osmolarity Test Tear Lactoferrin Test Tear Lysozyme Test Impression Cytology Biopsy of Labial Accessory Salivary Glands Ocular Ferning Test 46
Slide 47-

Tear Film Osmolarity Test Tear Samples are collected with hand-drawn micropippete from inferior marginal tear strip, without disturbing the ocular surface. Tear osmolarity is determined by a freezing point depression osmometer. Normal – 295 to 309 mOsm/litre Elevated in Dry Eyes. 47
Slide 48-

Impression Cytology To determine the goblet cell density of bulbar & palpebral conjunctiva. A strip of filter paper is gently pressed against the bulbar & palpebral conjunctiva with a glass end. Staining with Schiff’s agent & counter staining with haemotoxylin  graded with microscope. Dry Eyes  ↓ goblet cell counts. 48
Slide 49-

DEWS Dry eye severity grading scheme 49
Slide 50-

50
Slide 51-

Left Untreated, Chronic Dry EyeMay Become a Progressive Disorder Patients suffering from dry eye disease may move between severity levels and can become worse, if untreated. Disease management options can be adjusted for individual patients depending on disease severity 1Nelson et al. Adv Ther. 2000. 51
Slide 52-

Management 52
Slide 53-

Aims of Treatment Relieve discomfort Provide smooth optical surface Prevent structural ocular surface damage 53
Slide 54-

Modalities of treatment Preservation of existing tears Reduction of tear drainage Tear substitutes Treat any other associated eye disease which predisposes to dry eye Other options 54
Slide 55-

Preservation of existing tears Environmental modifications such as humidification, avoidance of wind/dusty or smoky environment, avoid central heating Lifestyle/workplace modifications taking regular breaks from reading or computer use lowering computer monitor below eye level increasing blink/fast blinking exercise discontinuing medications that exacerbate DED A small lateral tarsorrhaphy – useful in incomplete lid closure. 55
Slide 56-

Reduction of tear drainage Done by punctual occlusion Preserves natural tears & prolongs effect of artificial tears Greatest value in severe KCS who have not responded to frequent use of topical treatment. May be – Short term occlusion Permanent occlusion 56
Slide 57-

Temporary occlusion Collagen plugs are used. Dissolve in 1-2 weeks time. Initially all four puncta are occluded If epiphora occurs, then upper two plugs removed If patient is asymptomatic, then lower puncta are permanently occluded 57
Slide 58-

Reversible occlusion Reversible prolonged occlusion with silicone/ long acting collagen plugs (that dissolve in 2-6 wks). Problems – Extrusion Granuloma formation Distal migration. 58
Slide 59-

Permanent occlusion Done in severe KCS & repeated Schirmer < 2mm Should not be done in – Patients who develop epiphora following temporary occlusion of lower puncta Young patients as their tear production tends to fluctuate Done by cautery 59
Slide 60-

Tear substitutes Artificial Tear Drops used. Stabilize & thicken pre-corneal tear film . Prolongs tear film B.U.T. Keeps ocular surface wet & lubricated . Helps to repair ocular surface damage Keeps ocular surface smooth 60
Slide 61-

Tear substitutes Drops - Frequent instillation is required Preservative free drops are better Gels – Consists of carbomers Less frequent instillation required Ointments – Contains petroleum mineral oil & used at bedtime Mucolytic agents – 5 % acetylcysteine drops QID to disperse corneal filaments & mucous plaques. 61
Slide 62-

Eye Drops Cellulose derivatives – Hydroxypropyl methylcellulose Carboxymethylcellulose [more useful in lipid or mucous deficiency] Appropriate for mild cases. Polyvinyl alcohol – Better in aqueous deficiency Dose QID in mild cases ½ hrly – 2 hrly in severe cases Povidone Sodium chloride Hypromellose Sodium hyaluronate Polyethylene and propylene glycol 62
Slide 63-

Treatment of associated diseases Meibomian gland disease/ Blepharitis – Lid hygiene – warm compresses, lid massage Lid scrubs Systemic Doxycycline/ Azithromycin/ Roxitromycin Correction of eyelid abnormalities – blepharoptosis, lagophthalmos 63
Slide 64-

Other options Topical cyclosporine [0.05%, 0.1%] Reduces cell-mediated inflammation of lacrimal tissue  increase in goblet cells, reversal of squamous metaplasia of conjunctiva. Oral cholinergic agents (M3) like pilocarpine , cevimeline Effective in xerostomia & about 40% of KCS patients also obtain relief Botulinum toxin injection to orbicularis muscle – controls blepharospasm in severe dry eye. Sub-mandibular gland transplantation – for extreme dry eye. 64
Slide 65-

Level 1: Education and counselling Environmental management Elimination of offending systemic medications Preserved tear substitutes, allergy eye drops Level 2: If Level 1 treatments are inadequate, add: Unpreserved tears, gels, ointments Steroids Cyclosporine A Secretagogues Nutritional supplements The DEWS treatment recommendations were based on the modified severity grading (based on severity level) 65
Slide 66-

Level 3: If Level 2 treatments are inadequate, add: Tetracyclines Autologous serum tears Punctal plugs (after control of inflammation) Level 4: If Level 3 treatments are inadequate, add: Topical vitamin A Contact lenses Acetylcysteine Moisture goggles Surgery-Amniotic Membrane Transplanatation Limbal stem cell graft Keratoplasty 66
Slide 67-

Thank You 67